Heidi C Waters (Heidi Waters)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Hepatitis C Virus

Borderline Personality Disorder

Top Venues

ClinicoEconomics and outcomes research : CEOR

PharmacoEconomics

Journal of medical economics

Patient preference and adherence

This page only lists publications with an associated author ORCID identifier.

Publications

Julianna Catania, Steph Beaver, Rakshitha S Kamath, Emma Worthington, Minyi Lu, Hema Gandhi, Heidi C Waters, Daniel C Malone
Evaluation of Digital Mental Health Technologies in the United States: Systematic Literature Review and Framework Synthesis. JMIR mental health 11 (2024)
Dana B DiBenedetti, Katherine Kosa, Heidi C Waters, Dorothee Oberdhan
Understanding Patients' Experiences with Borderline Personality Disorder: Qualitative Interviews. Neuropsychiatric disease and treatment 19 (2023)
Heidi C Waters, Robert Stellhorn, Maëlys Touya, Heather M Fitzgerald, Sandipan Bhattacharjee, Citrome Leslie
The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics 26 (1) (2023)
Soon Nan Wee, Christian Liman, Heidi C Waters, Christy R Houle, Miguel E Renteria, Sankha Subhra Mukherjee, Subina Surendran, Joshua Marcovici, Malaak Brubaker, Stine Rasmussen Meehan, Anne de Jong-Laird, Augustus John Rush, Joydeep Sarkar
Life Engagement Improvement Following Initiation of Brexpiprazole Treatment in Patients with MDD: A Naturalistic, Retrospective Real-World Study. ClinicoEconomics and outcomes research : CEOR 15 (2023)
Soon Nan Wee, Christian Liman, Heidi C Waters, Christy R Houle, Miguel E Renteria, Sankha Subhra Mukherjee, Subina Surendran, Joshua Marcovici, Malaak Brubaker, Stine Rasmussen Meehan, Anne de Jong-Laird, Augustus John Rush, Joydeep Sarkar
Life Engagement Improvement Following Initiation of Brexpiprazole Treatment in Patients with MDD: A Naturalistic, Retrospective Real-World Study. ClinicoEconomics and outcomes research : CEOR 15 (2023)
Heidi C Waters, Robert Stellhorn, Maëlys Touya, Heather M Fitzgerald, Sandipan Bhattacharjee, Citrome Leslie
The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics (2023)
Michael Townsend, Kristin Pareja, Amy Buchanan-Hughes, Emma Worthington, David Pritchett, Malaak Brubaker, Christy Houle, Tenna Natascha Mose, Heidi C Waters
Antipsychotic-Related Stigma and the Impact on Treatment Choices: A Systematic Review and Framework Synthesis. Patient preference and adherence 16 (2022)
Marjanne A Piena, Natalie Houwing, Carla W Kraan, Xiaofeng Wang, Heidi C Waters, Craig Bennison
Response to Comment on "An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia". PharmacoEconomics 40 (12) (2022)
Marjanne A Piena, Natalie Houwing, Carla W Kraan, Xiaofeng Wang, Heidi C Waters, Ruth A Duffy, Suresh Mallikaarjun, Craig Bennison
An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia. PharmacoEconomics (2021)
Carolyn Martin, Eleena Koep, John White, Angela Belland, Heidi C Waters, Felicia Forma
Treatment Compliance Communications Between Patients with Severe Mental Illness and Treating Healthcare Providers: A Retrospective Study of Documentation Using Healthcare Reimbursement Claims and Medical Chart Abstraction. Pragmatic and observational research 12 (2021)